Jan Skvarka Buys 60,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company's stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL traded down $0.24 during mid-day trading on Friday, reaching $1.92. 1,635,276 shares of the company's stock were exchanged, compared to its average volume of 3,195,366. The firm has a market capitalization of $136.83 million, a price-to-earnings ratio of -0.77 and a beta of 1.81. The firm has a 50-day moving average price of $2.77 and a two-hundred day moving average price of $3.19. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.61 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $37,000. Aigen Investment Management LP purchased a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $41,000. Capstone Investment Advisors LLC bought a new position in Zentalis Pharmaceuticals during the third quarter worth about $48,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have issued reports on ZNTL. Wells Fargo & Company cut their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. UBS Group cut their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. HC Wainwright lowered their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. Guggenheim cut their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, November 15th. Finally, Wedbush reiterated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.